US equities |
TSLA $362.44 ▲+0.00% MU $931.24 ▲+0.00% SPCX $148.62 ▲+0.00% SNDK $1,394.83 ▲+0.00% SKHY $146.11 ▲+0.00% NVDA $217.23 ▲+0.00% AMD $562.23 ▲+0.00% INTC $95.22 ▼-0.16%
FinancialContent

Articles published by TriSalus Life Sciences

< Previous 1 2 Next >
News headline image
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Reports Second Quarter 2026 Results
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Proposes Public Offering
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
News headline image
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
< Previous 1 2 Next >